A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis

NCT07317700 PHASE3 RECRUITING

This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial. Successful trial participants were selected and assigned to either the experimental group or the control group in a 2:1 stratified manner, with the stratification factor being the Dynamic International Prognostic Scoring System (DIPSS) prognostic grading criteria. Continuously take the test drug/control drug until it meets the withdrawal criteria.

Details

Lead sponsor	Chengdu Zenitar Biomedical Technology Co., Ltd
Phase	PHASE3
Status	RECRUITING
Enrolment	105
Start date	Fri Feb 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Mar 30 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• MF

Interventions

• Flonoltinib 75mg
• Ruxolitinib Phosphate

Countries

China